Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Oncofertility
  • Reduced price

Clinical Atlas of PET

With Imaging Correlation

9780721639260
781.20 zł
703.08 zł Save 78.12 zł Tax included
Lowest price within 30 days before promotion: 703.08 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
This user-friendly atlas demonstrates all of the major clinical applications of PET scanning. Its case-based approach-with teaching points, pitfalls, and mimics-presents all of the material in a concise and practical manner. And, correlative cross-sectional images illustrate the clinical features depicted in PET findings.
Product Details
Saunders
31182
9780721639260
9780721639260

Data sheet

Publication date
2004
Issue number
1
Cover
hard cover
Pages count
448
Dimensions (mm)
216 x 276
Weight (g)
1651
  • Chapter 1: The Basics of PET

    Chapter 2: Approach to PET Image Interpretation, Normal Variants, and Benign Processes

    Chapter 3: Lung Cancer

    Case 1: SPN, positive, no other disease sites (proven adenocarcinoma).
    Case 2: SPN, positive (proven adenocarcinoma).
    Case 3: SPN, positive (proven recurrent squamous cell carcinoma).
    Case 4: SPN, positive (proven large cell carcinoma).
    Case 5: SPN, positive (proven squamous cell carcinoma).
    Case 6: SPN, negative, tuberculoma.
    Case 7: SPN, negative, aspergillosis.
    Case 8: SPN, negative, cocci granuloma.
    Case 9: SPN-positive, with hilar and/or mediastinal disease (proven large cell carcinoma).
    Case 10: SPN, positive, with false positive mediastinal disease (proven squamous cell carcinoma).
    Case 11: SPN-positive, with hilar and/or mediastinal disease (advanced aquamous cell carcinoma).
    Case 12: Lung cancer staging, primary positive, no other disease (large cell undifferentiated carcinoma).
    Case 13: Lung cancer staging, primary positive (proven adenocarcinoma).
    Case 14: Lung cancer staging, primary only positive (NSCLC), coexisting infiltrative lung disease.
    Case 15: Lung cancer staging, primary site only positive (proven squamous cell carcinoma).
    Case 16: Lung cancer staging, with subtle mediastinal involvement (squamous cell carcinoma).
    Case 17: Non-small cell lung cancer, with mediastinal involvement.
    Case 18: Lung cancer staging, with mediastinal disease (large cell carcinoma).
    Case 19: Lung cancer staging, with bone metastasis (adenocarcinoma).
    Case 20: Lung cancer staging, with bone metastases (large cell malignancy).
    Case 21: Lung cancer staging, Stage IV non-small cell lung cancer, with adrenal metastasis.
    Case 22: Lung cancer, restaging post-treatment, with adrenal metastasis (large cell carcinoma).
    Case 23: Squamous cell carcinoma, Stage IV, with axillary node involvement.
    Case 24: Lung cancer (SCC), with chest wall invasion.
    Case 25: Known lung cancer for staging, extensive disease (squamous cell carcinoma).
    Case 26: Lung cancer staging, extensive disease (NSCLC).
    Case 27: Lung cancer staging, small cell carcinoma.
    Case 28: Lung cancer staging, localized pleural involvement (NSCLC and adenocarcinoma).
    Case 29: Lung cancer staging, pleural adenocarcinoma.
    Case 30: Non-small cell lung carcinoma, metastatic to pleura.
    Case 31: Lung cancer restaging, treatment assessment (SCC).
    Case 32: Lung cancer restaging, radiation therapy effects (SCC).
    Case 33: Bilateral lung cancers.
    Case 34: Breast carcinoma pulmonary metastases mimicking synchronous lung cancers.
    Case 35: Bilateral lung cancers.
    Case 36: Pitfall: Bronchoalveolar cell carcinoma.
    Case 37: Pitfall: Bronchoalveolar cell carcinoma.
    Case 38: Pitfall: Bronchoalveolar cell carcinoma.
    Case 39: Pitfall: Lung cancer false positive, pulmonary infarct.
    Case 40: Pitfall: lung cancer false positive, active tuberculosis.
    Case 41: Pitfall: lung cancer false positive, sarcoidosis.
    Case 42: Pitfall: Lung cancer, size limitation.

    Chapter 4: Lymphoma

    Case 1: Lymphoma, limited stage disease, staging.
    Case 2: Lymphoma, staging, isolated neck disease.
    Case 3: Lymphoma, staging and treatment assessment, pulmonary parenchymal involvement.
    Case 4: Unexpected PET identification of limited stage visceral lymphoma.
    Case 5: Bulky thoracic NSHD, initial staging and residual mass treatment assessment.
    Case 6: Thoracic HD, initial staging and treatment assessment.
    Case 7: Thoracic and abdominal HD: initial staging, treatment assessment, marrow activation.
    Case 8: Lymphoma, nodal & visceral involvement, staging & treatment assessment, marrow activation.
    Case 9: Recurrent lymphoma, bone marrow involvement.
    Case 10: Recurrent pelvic NHL, radiation therapy follow-up.
    Case 11: Mantle cell lymphoma, radiation response.
    Case 12: Mediastinal recurrent lymphoma, response to chemotherapy.
    Case 13: Mesenteric NHL, residual mass assessment.
    Case 14: Lymphoma, staging & treatment assessment, head & neck presentation.
    Case 15: Recurrent lymphoma, pediatric patient.
    Case 16: Lymphoma follow-up, thymic rebound.

    Chapter 5: Melanoma

    Case 1: Staging, persistent disease at operative site
    Case 2: Initial and re-staging, disease progression despite chemotherapy.
    Case 3: Staging, unexpected additional disease site.
    Case 4: Staging, multiple unexpected additional disease sites.
    Case 5: Melanoma, restaging, solitary recurrent disease site (axilla).
    Case 6: Restaging, recurrent facial disease.
    Case 7: Restaging, progressive facial recurrences.
    Case 8: Melanoma, restaging, lung and brain metastases.
    Case 9: Restaging; lung, hilar, liver and osseous metastases.
    Case 10: Restaging, extensive disease, treatment assessment.
    Case 11: Restaging, advanced disease (carcinomatosis).

    Chapter 6: Colorectal Cancer

    Case 1: Initial staging, no additional disease site (rectal cancer).
    Case 2: Initial staging, involved adjacent lymph node.
    Case 3: Initial staging, distant metastases.
    Case 4: Restaging, solitary liver metastasis.
    Case 5: Restaging, recurrent hepatic metastasis.
    Case 6: Restaging, solitary liver metastasis.
    Case 7: Restaging, retroperitoneal nodal recurrence, assessment of post-treatment pre-sacral mass.
    Case 8: Restaging, pelvic recurrences.
    Case 9: Restaging, pre-sacral recurrence.
    Case 10: Restaging, pulmonary parenchymal and pleural recurrences.
    Case 11: Recurrent colorectal carcinoma, rising CEA, bone metastases.
    Case 12: Colon cancer, liver metastasis, treatment effect (RF ablation).
    Case 13: Liver metastasis, assessment of RF ablation efficacy.
    Case 14: Liver metastases, surgical and interventional treatment effects.
    Case 15: Liver metastases, chemotherapy efficacy.
    Case 16: Pitfall: Recurrence, sub-centimeter lung metastases.
    Case 17: Pitfall: Coexisting benign disease (viral axillary adenitis).

    Chapter 7: Other Gastrointestinal Cancers

    Case 1: Proximal esophageal squamous cell carcinoma.
    Case 2: Distal esophageal adenocarcinoma, with gastro-hepatic nodal involvement.
    Case 3: Esophageal carcinoma, superior mediastinal paraesophageal nodal involvement.
    Case 4: Distal esophageal SCC.
    Case 5: Distal esophageal adenocarcinoma, with gastric cardia extension and paragastric nodal involvement.
    Case 6: Gastric carcinoma, with retroperitoneal nodal metastases.
    Case 7: Gastric carcinoma, with peritoneal carcinomatosis.
    Case 8: Pancreatic adenocarcinoma.
    Case 9: Locally recurrent pancreatic carcinoma.
    Case 10: Recurrent pancreatic carcinoma, metastatic to liver and brain.
    Case 11: Ampullary adenocarcinoma, with local nodal involvement.
    Case 12: Cholangiocarcinoma, with liver metastasis.
    Case 13: Recurrent cholangiocarcinoma, drop metastasis.
    Case 14: Suspected residual gallbladder carcinoma.

    Chapter 8: Head and Neck Cancer

    Case 1: Normal head and neck anatomy example.
    Case 2: Glottic squamous cell carcinoma, initial diagnosis.
    Case 3: Initial staging, BOT squamous cell carcinoma, with nodal metastasis at presentation.
    Case 4: Locally advanced base of tongue squamous cell carcinoma, with bilateral necrotic lymph node metastases.
    Case 5: Metastatic squamous cell carcinoma, cervical lymph node presentation, primary lesion search.
    Case 6: Hard palate squamous cell carcinoma, radiation therapy planning.
    Case 7: Recurrent maxillary non-small cell malignancy.
    Case 8: Recurrent and progressive squamous cell carcinoma.
    Case 9: Nasopharyngeal squamous cell carcinoma, with bone metastases.
    Case 10: Squamous cell carcinoma, metastatic to thoracic spine, incipient cord compression presentation.

    Chapter 9: Breast Cancer

    Case 1: Focal breast activity due to an unsuspected breast cancer.
    Case 2: Breast cancer, initial staging, axillary nodal presentation, primary search and internal mammary adenopathy.
    Case 3: Breast cancer restaging, normal post-lumpectomy and radiation breast findings.
    Case 4: Post surgical biopsy scar, post lumpectomy for infiltrating ductal carcinoma.
    Case 5: Treated inflammatory breast cancer.
    Case 6: Recurrent inflammatory breast cancer.
    Case 7: Breast cancer restaging, in situ neoadjuvantly treated infiltrating lobular carcinoma, with diffuse blastic bone metastases.
    Case 8: Breast cancer restaging, bone metastases.
    Case 9: Breast cancer restaging, active bone metastases, treated liver metastases.
    Case 10: Recurrent breast cancer, with extensive liver metatases.
    Case 11: Breast cancer restaging, solitary liver metatasis.
    Case 12: Recurrent breast cancer, with chest wall and lung parenchymal disease.
    Case 13: Breast cancer restaging, axillary and chest wall involvement and bone metastases.
    Case 14: Breast cancer restaging, extensive local and nodal recurrence.
    Case 15: Breast cancer restaging, local and nodal recurrences in axilla, supraclavicular neck and mediastinum.
    Case 16: Breast cancer restaging; mediastinal, neck and supraclavicular nodal recurrences.
    Case 17: Breast cancer restaging, hilar nodal involvement, progression to liver and bone metastases.
    Case 18: Restaging, thoracic (nodal and pulmonary parenchymal) metastases.
    Case 19: Breast Cancer restaging, assessment of chemotherapy efficacy, mediastinal and bone metastases.

    Chapter 10: Miscellaneous Tumors

    Case 1: Recurrent thyroid carcinoma, lungs and neck.
    Case 2: Recurrent thyroid carcinoma, isolated neck lymph node.
    Case 3: Recurrent thyroid carcinoma to neck, low metabolic rate.
    Case 4: Pitfall: Suspected recurrent thyroid carcinoma to mediastinum, false positive (thymus)
    Case 5: In situ primary, presenting with pleural metastases
    Case 6: Sarcomatoid renal cell carcinoma, with retroperitoneal metastases
    Case 7: In situ primary, with IVC tumor extension
    Case 8: Renal cell carcinoma, lung metastasis.
    Case 9: Recurrent renal cell carcinoma, hilar and vertebral metastases
    Case 10: Locally recurrent clear cell renal cell carcinoma, with lung metastases
    Case 11: Widely metastatic testicular carcinoma, response to chemotherapy
    Case 12: Suspected recurrence, disseminated sarcoidosis
    Case 13: In situ primary transitional cell carcinoma
    Case 14: Widely metastatic transitional cell carcinoma
    Case 15: Widely metastatic prostate cancer, dedifferentiated
    Case 16: Benign adrenal hemangioendothelioma
    Case 17: Recurrent ovarian carcinoma, response to chemotherapy
    Case 18: Recurrent ovarian carcinoma, with parathyroid adenoma
    Case 19: Local recurrence of cervical carcinoma, pararectal region with synchronous lung colon carcinoma metastasis
    Case 20: Widely metastatic cervical carcinoma (brain, porta hepatic, supraclavicular and presacral)
    Case 21: Uterine corpus carcinoma, with vaginal metastasis
    Case 22: Unsuspected recurrent leiomyosarcoma to multiple muscles
    Case 23: Synovial sarcoma, metastatic to lung
    Case 24: Recurrent intraabdominal leiomyosarcoma
    Case 25: Recurrent thoracic liposarcoma
    Case 26: Ewings sarcoma follow-up
    Case 27: Residual leiomyosarcoma, post operative evaluation for residual disease
    Case 28: Malignant thymoma, pleural recurrence
    Case 29: Pitfall: Inflammatory reaction, suspected anterior mediastinal thymoma
    Case 30: Multiple myeloma, initial staging
    Case 31: Multiple discrete lesions, known disease follow-up
    Case 32: Multiple myeloma, diffusely infiltrative, poorly demonstrated on PET
    Case 33: Kaposis sarcoma (non-AIDS)
    Case 34: Bowens (multiple squamous cell carcinoma)

    Chapter 11: Neurologic PET Applications

    Case 1: Normal brain PET: guidelines for image interpretation.
    Case 2: Recurrent glioblastoma multiforme (differentiation from radiation necrosis).
    Case 3: Lung cancer metastasis, gamma knife follow-up.
    Case 4: Low-grade oligodendroglioma, initial diagnosis.
    Case 5: Oligodendroglioma, tumor differential diagnosis.
    Case 6: Low-grade glioma, transformation.
    Case 7: MCA infarct.
    Case 8: Radiation necrosis, residual oligodendroglioma.
    Case 9: Radiation necrosis, s/p scalp melanoma therapy.
    Case 10: Bitemporal radiation necrosis, s/p nasopharyngeal carcinoma therapy.
    Case 11: Temporal radiation necrosis, s/p pre-auricular basal cell carcinoma therapy, abnormal brain SPECT.
    Case 12: Alzheimers.
    Case 13: Alzheimers.
    Case 14: Picks (frontal lobe dementia).
    Case 15: Primary cerebellar degeneration.
    Case 16: Temporal lobe hypometabolism

    Chapter 12: Cardiac PET Applications

    Case 1: Myocardial viability study: Normal example
    Case 2: Myocardial viability study: Patient with non-Q wave MI and CHF, with abnormal thallium viability study
    Case 3: Myocardial viability study: Patient with known CAD, post MI and PTCA, with recurrent angina and abnormal SPECT
    Case 4: Myocardial viability study: Patient with chronic CHF post MI, being considered for percutaneous revascularization for fatigue and chest pain
    Case 5: Myocardial viability study: Nonsurgical candidate patient with recurrent symptoms, with abnormal SPECT, being considered for repeat percutaneous intervention
    Case 6: Myocardial viability study: Diabetic patient with multi-vessel CAD and ischemic cardiomyopathy, being considered for CABG revascularization
    Case 7: Myocardial viability study: Patient with prior MI, CABG, PTCA and ischemic cardiomyopathy, with matched perfusion/metabolism defects
    Case 8: Myocardial viability study: Patient with long-standing CAD, post multiple revascularization procedures, with persistent angina and dypnea and recurrent disease by angiography
    Case 9: Myocardial viability study: Diabetic, vasculopathic, high surgical risk patient, with abnormal SPECT and poor LV function, being considered for CABG
Comments (0)

  • Frequently purchased together

    No products available